Ocuphire Pharma Investor Day Presentation Deck | Slidebook.io

Ocuphire Pharma Investor Day Presentation Deck

January 2022, 114 slides

investor day | Ocuphire Pharma

disclosures and forward looking statements | Ocuphire Pharma

investor day agenda speakers we | Ocuphire Pharma

company overview | Ocuphire Pharma

restoring vision and clarity for your eyes today and tomorrow innovation performance execution disruption zeta lynx lalo aes cob ule | Ocuphire Pharma

ophthalmology an attractive sector | Ocuphire Pharma

drug development history and patents | Ocuphire Pharma

pipeline clinical milestones | Ocuphire Pharma

| Ocuphire Pharma

i program update university medical group | Ocuphire Pharma

chemistry and | Ocuphire Pharma

history and ref inhibition mechanism | Ocuphire Pharma

in validation of mechanism of action | Ocuphire Pharma

effects in normal cells | Ocuphire Pharma

preclinical enabling studies | Ocuphire Pharma

preclinical data oral blocks | Ocuphire Pharma

human and safety summary | Ocuphire Pharma

phase clinical trials data supporting the zeta trial | Ocuphire Pharma

phase clinical trials data supporting the zeta trial rat aches high levels in rat eye is orally | Ocuphire Pharma

subject exposure across prior clinical trials subjects | Ocuphire Pharma

safety summary from phase and phase studies way | Ocuphire Pharma

addressing unmet needs in retina | Ocuphire Pharma

clinical unmet need in diabetic retinal diseases a i invasive | Ocuphire Pharma

diabetic is a progressive vision threatening disease | Ocuphire Pharma

key clinical landscape in diabetic and | Ocuphire Pharma

zeta phase clinical trial in | Ocuphire Pharma

zeta phase design placebo bid | Ocuphire Pharma

key eligibility criteria in zeta | Ocuphire Pharma

why is an important its | Ocuphire Pharma

enrollment update on zeta patients enrolled | Ocuphire Pharma

comparison of subject exposure before and after zeta subjects | Ocuphire Pharma

characteristics for zeta trial interim | Ocuphire Pharma

masked safety findings from ongoing zeta trial | Ocuphire Pharma

masked interim safety findings from zeta trial | Ocuphire Pharma

broad opportunities to treat retinal diseases with platform treatments proven novel mechanism as | Ocuphire Pharma

large global us market opportunity in retinal disease me | Ocuphire Pharma

what important efficacy signal safety non invasive treatment option guidance physician patients efficacy signal safety non invasive treatment option | Ocuphire Pharma

for diabetic question answer | Ocuphire Pharma

summary of program | Ocuphire Pharma

reversal of mydriasis overview | Ocuphire Pharma

| Ocuphire Pharma

problem dilated eyes for exams and procedures | Ocuphire Pharma

current off label landscape for | Ocuphire Pharma

differentiated as an alpha blocker | Ocuphire Pharma

clinical data for reversing dilations | Ocuphire Pharma

program evaluating for the reversal of mydriasis | Ocuphire Pharma

phase registration trial design | Ocuphire Pharma

participant characteristics | Ocuphire Pharma

phase trial met primary | Ocuphire Pharma

study eye and non study eye | Ocuphire Pharma

responders returning to pupil size by iris color | Ocuphire Pharma

mean pupil size over time after maximum pupil dilation | Ocuphire Pharma

mean pupil diameter over time by mydriatic agent | Ocuphire Pharma

gain of visual function accommodation | Ocuphire Pharma

safety findings after dilation with mydriatic agent | Ocuphire Pharma

submission targeted in late | Ocuphire Pharma

what important efficacy signal safety label expansion guidance physician patients efficacy signal safety patient experience in drops | Ocuphire Pharma

market opportunity and commercialization | Ocuphire Pharma

patients are vocal about the negative effects of mydriasis i i i | Ocuphire Pharma

importance of dilations | Ocuphire Pharma

bottom up calculation of annual dilated eye exams | Ocuphire Pharma

market research methodology by | Ocuphire Pharma

reversal of mydriasis market opportunity a estimated us | Ocuphire Pharma

why rev eyes is not a for future sales | Ocuphire Pharma

market opportunity and commercialization | Ocuphire Pharma

perspective from practice administrators on reversing dilations | Ocuphire Pharma

commercial activities in | Ocuphire Pharma

go to market strategy for | Ocuphire Pharma

practice implementation models | Ocuphire Pharma

for reversal of mydriasis question answer axe | Ocuphire Pharma

summary of reversal of mydriasis program | Ocuphire Pharma

presbyopia program | Ocuphire Pharma

pupil modulation eye drops for presbyopia | Ocuphire Pharma

the time for presbyopia drops evolving toward options eras piano a approval of eye drop a new moment in | Ocuphire Pharma

what is the optimal pupil size | Ocuphire Pharma

with as adjunctive therapy in presbyopia | Ocuphire Pharma

with low dose pilocarpine as adjunct therapy | Ocuphire Pharma

presbyopia phase trial design eaten | Ocuphire Pharma

demographics and characteristics mean read moan | Ocuphire Pharma

met primary secondary | Ocuphire Pharma

planned efficacy met by | Ocuphire Pharma

improvement in functional near vision | Ocuphire Pharma

mean pupil diameter over time a | Ocuphire Pharma

photopic and mesopic distance vision effects | Ocuphire Pharma

safety findings across all arms | Ocuphire Pharma

what important guidance physician patients | Ocuphire Pharma

alone in presbyopia i | Ocuphire Pharma

study design assessed alone efficacy ace | Ocuphire Pharma

meets planned efficacy at hours | Ocuphire Pharma

letter gain in with at hours | Ocuphire Pharma

improvement in functional near vision | Ocuphire Pharma

functional vision durability wye | Ocuphire Pharma

post efficacy across presbyopia ages wey | Ocuphire Pharma

presbyopia drops next steps and competitive landscape | Ocuphire Pharma

two treatment options for spectrum of presbyopic patients pursuing product labels for drop and drop options for the treatment of presbyopia initiating phase program in mid for both labels mid art dian | Ocuphire Pharma

potential best in class presbyopia drop | Ocuphire Pharma

presbyopia eye drops competitive landscape | Ocuphire Pharma

large and growing presbyopia market hire | Ocuphire Pharma

presbyopia is a burgeoning opportunity asses market the | Ocuphire Pharma

key findings from market research on presbyopia million | Ocuphire Pharma

presbyopia market segments presbyopes in the us hyperopes a myopes | Ocuphire Pharma

is the first approved eyedrop for presbyopia | Ocuphire Pharma

for presbyopia question answer | Ocuphire Pharma

summary of and presbyopia program | Ocuphire Pharma

closing remarks | Ocuphire Pharma

management team page tech a by | Ocuphire Pharma

world class medical advisory board | Ocuphire Pharma

board of directors | Ocuphire Pharma

thanks to our network of partners on am | Ocuphire Pharma

track record of achieving milestones exciting news cadence | Ocuphire Pharma

overall highlights from investor day | Ocuphire Pharma

thank you for joining us click here for the recorded event investor day | Ocuphire Pharma

See More

Ocuphire Pharma

Investor Day Presentation Decks

Explore Topics

Clinical trial

Recent decks by Ocuphire Pharma

Investor Presentation

November 2023

Investor Presentation

August 2023

Investor Presentation

May 2023

Results

January 2023

See all presentations by Ocuphire Pharma (10 decks)

Recent decks by Ocuphire Pharma

See all presentations (10 decks)

Investor Presentation

November 2023

Investor Presentation

August 2023

Investor Presentation

May 2023

Results

January 2023

Search Thousands of Presentations by World Leading Companies

Trending:

Addressable Market

Management Team

Investment Highlights